Korro Bio, Inc. (NASDAQ:KRRO – Free Report) – HC Wainwright decreased their Q3 2024 earnings per share estimates for shares of Korro Bio in a research note issued to investors on Wednesday, August 14th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($2.40) per share for the quarter, down from their prior estimate of ($2.24). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.64) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.45) EPS, FY2024 earnings at ($9.72) EPS, Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($2.56) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.17) EPS.
Korro Bio (NASDAQ:KRRO – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04).
Check Out Our Latest Research Report on KRRO
Korro Bio Stock Down 2.6 %
NASDAQ:KRRO opened at $43.91 on Friday. Korro Bio has a one year low of $9.15 and a one year high of $97.91. The stock has a 50 day moving average price of $41.10 and a 200 day moving average price of $53.05.
Institutional Investors Weigh In On Korro Bio
A number of institutional investors have recently added to or reduced their stakes in the business. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Korro Bio during the 4th quarter worth approximately $53,648,000. Eventide Asset Management LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $26,185,000. 72 Investment Holdings LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $13,269,000. Driehaus Capital Management LLC acquired a new position in shares of Korro Bio during the 2nd quarter worth approximately $3,958,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Korro Bio during the 4th quarter worth approximately $4,352,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.
Korro Bio Company Profile
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Stories
- Five stocks we like better than Korro Bio
- 3 Small Caps With Big Return Potential
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 8/12 – 8/16
- Canadian Penny Stocks: Can They Make You Rich?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.